|
市場調査レポート
商品コード
1671873
鎌状赤血球症治療市場：治療タイプ別、年齢層別、投与経路別、エンドユーザー別、流通チャネル別、地域別Sickle Cell Disease Treatment Market, By Treatment Type, By Age Group, By Route of Administration, By End User, By Distribution Channel, By Geography |
||||||
カスタマイズ可能
|
|||||||
| 鎌状赤血球症治療市場：治療タイプ別、年齢層別、投与経路別、エンドユーザー別、流通チャネル別、地域別 |
|
出版日: 2025年01月08日
発行: Coherent Market Insights
ページ情報: 英文 140 Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 目次
世界の鎌状赤血球症治療市場は、2025年には32億米ドルと推定され、2032年には88億1,000万米ドルに達すると予測され、2025年から2032年までのCAGRは15.6%です。
| レポート範囲 | レポート詳細 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025年の市場規模 | 32億米ドル |
| 実績データ | 2020年から2024年まで | 予測期間 | 2025年から2032年 |
| 予測期間：2025年～2032年 CAGR： | 15.60% | 2032年の価値予測 | 88億1,000万米ドル |
鎌状赤血球症は、異常な赤血球を引き起こす遺伝性血液疾患です。体内の組織や臓器への酸素供給に影響を及ぼします。この疾患は世界中、特にサハラ以南のアフリカ、中東、インド亜大陸、地中海地域、中南米で流行しています。診断率や検出率の上昇に加え、高度な治療オプションの利用可能性に関する意識の高まりもあり、市場は今後数年間で有利な機会を示すと予測されています。新しい薬物療法や遺伝子治療に基づく治療アプローチの開発も市場拡大に拍車をかけています。
市場力学：
新薬や今後のパイプライン候補の開発に注力する研究活動の活発化が、世界の鎌状赤血球症治療市場の主要な成長要因となっています。新興国におけるヘルスケア支出の増加と有利な償還政策が、市場の成長をさらに後押ししています。骨髄移植のような根治療法の採用拡大も市場を後押ししています。しかし、先進的な治療アプローチに伴う高額な費用や、未発達地域における認知度の低さが市場成長を抑制しています。遺伝子治療に基づく治療の採用が増加していることは、市場関係者にとって大きなチャンスです。また、手ごろな価格の再生治療オプションの開発も、近い将来に新たな道を切り開く可能性を秘めています。
本調査の主な特徴
本レポートでは、世界の鎌状赤血球症治療市場を詳細に分析し、2024年を基準年とした予測期間（2025-2032年）の市場規模および複合年間成長率（CAGR%）を掲載しています。
また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。
また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
世界の鎌状赤血球症治療市場における主要企業を、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいてプロファイルしています。
本調査の対象となる主要企業には、Novartis AG、Emmaus Medical Inc.、Agios Pharmaceuticals Inc.、Bluebird Bio、Pfizer Inc.、Bristol-Myers Squibb Company、Celgene Corporation、GSK（GlaxoSmithKline）、Sanofi S.A.、Merck &Co.、Amgen Inc.、Bayer AG、Teva Pharmaceutical Industries Ltd.、中外製薬株式会社、第一三共株式会社などがあります。
本レポートの洞察により、マーケティング担当者や各企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関して、十分な情報に基づいた意思決定を行うことができます。
世界の鎌状赤血球症治療市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者を対象としています。
利害関係者は、世界の鎌状赤血球症治療市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。
目次
第1章 調査の目的と前提条件
- 調査目的
- 前提条件
- 略語
第2章 市場の展望
- レポートの説明
- 市場の定義と範囲
- エグゼクティブサマリー
第3章 市場力学、規制、動向分析
- 市場力学
- 機会
- 影響分析
- 主な発展
- 規制シナリオ
- 製品の発売/承認
- PEST分析
- PORTERの分析
- 合併と買収のシナリオ
- 業界動向
第4章 鎌状赤血球症治療の世界市場、治療タイプ別、2020年～2032年
- 輸血
- 骨髄移植
- 薬物療法
- ヒドロキシウレア療法
- オクスブリタ
- アダクヴェオ
- 疼痛管理薬
- その他
第5章 鎌状赤血球症治療の世界市場、年齢グループ別、2020年～2032年
- 成人
- 小児科
- 高齢者向け
第6章 鎌状赤血球症治療の世界市場、投与経路別、2020年～2032年
- 経口
- 非経口
第7章 鎌状赤血球症治療の世界市場、エンドユーザー別、2020年～2032年
- 病院
- 専門クリニック
- ホームケア設定
- その他
第8章 鎌状赤血球症治療の世界市場、流通チャネル別、2020年～2032年
- 病院薬局
- 小売薬局
- オンライン薬局
第9章 世界の鎌状赤血球症治療市場、地域別、2020年～2032年
- 北米
- ラテンアメリカ
- 欧州
- アジア太平洋
- 中東
- アフリカ
第10章 競合情勢
- Novartis AG
- Emmaus Medical Inc.
- Agios Pharmaceuticals Inc.
- Bluebird Bio
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Celgene Corporation
- GSK（GlaxoSmithKline）
- Sanofi S.A.
- Merck & Co., Inc.
- Amgen Inc.
- Bayer AG
- Teva Pharmaceutical Industries Ltd.
- Chugai Pharmaceutical Co., Ltd.
- Daiichi Sankyo Company, Limited
第11章 アナリストの推奨事項
- 運命の輪
- アナリストの見解
- 一貫した機会マップ
第12章 参考文献と調査手法
- 参考文献
- 調査手法
- 出版社について
The Global Sickle Cell Disease Treatment Market is estimated to be valued at USD 3.20 Bn in 2025 and is expected to reach USD 8.81 Bn by 2032 exhibiting a compound annual growth rate (CAGR) of 15.6% from 2025 to 2032
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 3.20 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 15.60% | 2032 Value Projection: | USD 8.81 Bn |
Sickle cell disease is a genetic blood disorder causing abnormal red blood cells. It affects the oxygen supply to tissues and organs in the body. This disorder is prevalent across worldwide, especially in Sub-Saharan Africa, the Middle East, Indian subcontinent, Mediterranean regions, and South and Central America. With growing diagnostic and detection rates, coupled with rising awareness regarding availability of advanced treatment options, the market is projected to showcase lucrative opportunities over the coming years. The development of new drug therapies and gene-therapy based treatment approaches are also fueling the market expansion.
Market Dynamics:
Increasing research activities focusing on developing novel drugs and upcoming pipeline candidates are acting as a key growth driver for global sickle cell disease treatment market. Rising healthcare expenditures in emerging nations and favorable reimbursement policies are further supporting the market growth. Growing adoption of curative therapies such as bone marrow transplantation is also boosting the market. However, high costs associated with advanced treatment approaches and lack of awareness in underdeveloped regions are restraining the market growth. Rising adoption of gene-therapy based treatments presents significant opportunities for market players. Development of affordable regenerative treatment options also holds potential to create new avenues in the near future.
Key Features of the Study:
This report provides in-depth analysis of the global sickle cell disease treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global sickle cell disease treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis AG, Emmaus Medical Inc., Agios Pharmaceuticals Inc., Bluebird Bio, Pfizer Inc., Bristol-Myers Squibb Company, Celgene Corporation, GSK (GlaxoSmithKline), Sanofi S.A., Merck & Co., Inc., Amgen Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co., Ltd., and Daiichi Sankyo Company, Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global sickle cell disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global sickle cell disease treatment market
Market Segmentation
- By Treatment Type Insights (Revenue, USD Bn, 2020 - 2032)
- Blood Transfusion
- Bone Marrow Transplant
- Pharmacotherapy
- Hydroxyurea Therapy
- Oxbryta
- Adakveo
- Pain Management Drugs
- Others
- By Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adults
- Pediatric
- Geriatric
- By Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
- By End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Specialty Clinics
- Homecare Settings
- Others
- By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novartis AG
- Emmaus Medical Inc.
- Agios Pharmaceuticals Inc.
- Bluebird Bio
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Celgene Corporation
- GSK (GlaxoSmithKline)
- Sanofi S.A.
- Merck & Co., Inc.
- Amgen Inc.
- Bayer AG
- Teva Pharmaceutical Industries Ltd.
- Chugai Pharmaceutical Co., Ltd.
- Daiichi Sankyo Company, Limited
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Sickle Cell Disease Treatment Market, By Treatment Type
- Global Sickle Cell Disease Treatment Market, By Age Group
- Global Sickle Cell Disease Treatment Market, By Route of Administration
- Global Sickle Cell Disease Treatment Market, By End User
- Global Sickle Cell Disease Treatment Market, By Distribution Channel
- Global Sickle Cell Disease Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Sickle Cell Disease Treatment Market, By Treatment Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Blood Transfusion
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bone Marrow Transplant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pharmacotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hydroxyurea Therapy
- Oxbryta
- Adakveo
- Pain Management Drugs
- Others
5. Global Sickle Cell Disease Treatment Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Sickle Cell Disease Treatment Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parentral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Sickle Cell Disease Treatment Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Sickle Cell Disease Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Sickle Cell Disease Treatment Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Emmaus Medical Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Agios Pharmaceuticals Inc.
- Bluebird Bio
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Celgene Corporation
- GSK (GlaxoSmithKline)
- Sanofi S.A.
- Merck & Co., Inc.
- Amgen Inc.
- Bayer AG
- Teva Pharmaceutical Industries Ltd.
- Chugai Pharmaceutical Co., Ltd.
- Daiichi Sankyo Company, Limited
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
